The biggest stories of the day delivered to your inbox.

NTLA reports better-than-expected first-quarter 2025 results. The company provides updates on its pipeline candidates. Shares rise.

Intellia will present additional data from the ongoing Phase 1/2 study in an oral presentation at the European Academy of ...

On track to complete enrollment of the global Phase 3 HAELO study in hereditary angioedema (HAE) in the third quarter of 2025Dosed first patient in the global Phase 3 MAGNITUDE-2 study evaluating nexi ...

CRISPR Therapeutics and Intellia face 2025 volatility, but CRSP’s strong cash and launches make it more attractive than NTLA.

Discover Q1 2025 earnings insights from Intellia Therapeutics (NTLA): Phase 3 progress, RMAT milestones, financial outlook, and competitive gene editing edge.

and nexiguran ziclumeran (nex-z) for ATTR amyloidosis as it anticipates its first commercial launch in 2027. The discontinued programmes are headed by NTLA-3001, an in vivo CRISPR drug developed ...

Last week’s poll shows that vivo has a hit on its hands with the X200 Ultra – which makes its reluctance to sell it globally even more confounding. Even the X200s did pretty okay, even though ...

With flagship smartphones pushing boundaries each year, the Vivo X200 Ultra and iPhone 16 Pro Max represent the pinnacle of Android and iOS innovation. This comparison matters because it ...

The vivo V50e has the Dimensity 7300 SoC under the hood, like its predecessor V40e. It's paired with 8GB RAM, and you get two storage options - 128GB and 256GB. The V50e runs Android 15-based ...

Vivo has launched the X200 Ultra smartphone in China. The X200 Ultra has an optional telephoto converter lens, enabling 8.7x native zoom via the phone’s 200MP periscope camera. The phone also ...